Talquetamab Combo Data Warrant Further Research in R/R Multiple Myeloma
Findings from RedirecTT-1 show responses across different dose levels of talquetamab/teclistamab among those with multiple myeloma.
Related Articles
Novel regimen greatly reduced chronic GVHD in phase 2 study at Fred Hutch
A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in preventing moderate to severe…
FDA Grants Key Oncology Approvals and Designations in January 2025
Here is a look back on all the FDA happenings from the month of January 2025.
2024 Blood Journal Contest
9th Annual Blood Cover Art Contest is now open. In recognition of authors who published in Blood and images used in advancement of science, we…
Podcast: The Scope of US Medical Debt w/ Kinika Young | Health Affairs Podcast
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…
January 2025 Early Career Newsletter – American Society for Radiation Oncology (ASTRO)
This issue includes important information on the committee’s initiatives for the upcoming year, including recording podcasts, organizing informal meetups at different society meetings, collaborating with…
Standard of care for frontline treatment of non-V600E-specific pLGG tumors
The experts in pediatric low-grade gliomas (pLGG) delineate the standard of care for frontline treatment of tumors not harboring the BRAF V600E mutation, outlining current…
Podcast: The Scope of US Medical Debt w/ Kinika Young | Health Affairs Podcast
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…
Fox Chase Cancer Center’s Dr. Eric Goodlev Named a Fellow of the American Academy of Hospice and Palliative Medicine
PHILADELPHIA (January 31, 2025) — Eric Goodlev, MD, an Associate Professor in the Supportive Oncology and Palliative Care Program at Fox Chase Cancer Center, was recently named…
